The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
We sought to analyze the efficacy of adalimumab in active noninfectious uveitis, and evaluate its efficacy and safety for the managementof refractory noninfectious uveitis in Korean patients. A retrospective observational study was conducted. A total of 23eyes of 14 Korean patients with noninfectious uveitis refractory to conventional treatment, including corticosteroid and immunosuppressiveagents, were treated with adalimumab between December 2017 and February 2020. The primary outcomes were vitreoushaziness grades, anterior chamber cell grades, and central macular thickness measured prior to injection and at 1, 3, 6, and12 months after the first adalimumab injection. Among the 23 eyes, 14 eyes (60.9%) were diagnosed with panuveitis and 9 eyes(39.1%) with posterior uveitis [mean follow-up period: 22.3 months (7–27)]. The most common etiologic diagnoses requiring adalimumabinjection were Behçet’s disease (9 eyes, 39.1%), followed by undifferentiated inflammation (6 eyes, 26.1%), Vogt-Koyanagi-Harada disease (3 eyes, 13.0%), psoriasis (2 eyes, 8.7%), serpiginous chorioretinopathy (2 eyes, 8.7%), and systemic lupus erythematosus(1 eye, 4.3%). At the 1-year follow-up after the first injection, anterior chamber cell grade decreased from 0.5±0.4 to0.3±0.4, and vitreous haziness grade decreased from 1.1±1.1 to 0.3±0.5 (p<0.05). Central macular thickness improved from347.2±98.1 μm to 264.3±61.1 μm (p<0.05). Adalimumab injection in patients with refractory noninfectious uveitis decreased theanterior chamber cell grade, vitreous haziness grade, and central macular thickness with no severe side effect. Overall, adalimumabinjection may, therefore, be an effective and relatively safe treatment modality for noninfectious uveitis in Korean patients.
Abstract
We sought to analyze the efficacy of adalimumab in active noninfectious uveitis, and evaluate its efficacy and safety for the managementof refractory noninfectious uveitis in Korean patients. A retrospective observational study was conducted. A total of 23eyes of 14 Korean patients with noninfectious uveitis refractory to conventional treatment, including corticosteroid and immunosuppressiveagents, were treated with adalimumab between December 2017 and February 2020. The primary outcomes were vitreoushaziness grades, anterior chamber cell grades, and central macular thickness measured prior to injection and at 1, 3, 6, and12 months after the first adalimumab injection. Among the 23 eyes, 14 eyes (60.9%) were diagnosed with panuveitis and 9 eyes(39.1%) with posterior uveitis [mean follow-up period: 22.3 months (7–27)]. The most common etiologic diagnoses requiring adalimumabinjection were Behçet’s disease (9 eyes, 39.1%), followed by undifferentiated inflammation (6 eyes, 26.1%), Vogt-Koyanagi-Harada disease (3 eyes, 13.0%), psoriasis (2 eyes, 8.7%), serpiginous chorioretinopathy (2 eyes, 8.7%), and systemic lupus erythematosus(1 eye, 4.3%). At the 1-year follow-up after the first injection, anterior chamber cell grade decreased from 0.5±0.4 to0.3±0.4, and vitreous haziness grade decreased from 1.1±1.1 to 0.3±0.5 (p<0.05). Central macular thickness improved from347.2±98.1 μm to 264.3±61.1 μm (p<0.05). Adalimumab injection in patients with refractory noninfectious uveitis decreased theanterior chamber cell grade, vitreous haziness grade, and central macular thickness with no severe side effect. Overall, adalimumabinjection may, therefore, be an effective and relatively safe treatment modality for noninfectious uveitis in Korean patients.
참고문헌 (15)
- Chang JH, "Uveitis : a global perspective", Ocul Immunol Inflamm, 10, pp.263~279 (2002)
- Lee JT, "Adalimumab for the treatment of refractory active and inactive non-infectious uveitis", Br J Ophthalmol, 102, pp.1672~1678 (2018)
- Jaffe GJ, "Adalimumab in patients with active noninfectious uveitis", N Engl J Med, 375, pp.932~943 (2016)
- Tsirouki T, "A focus on the epidemiology of uveitis", Ocul Immunol Inflamm, 26, pp.2~16 (2018)
- Díaz-Llopis M, "Treatment of refractory uveitis with adalimumab : a prospective multicenter study of 131 patients", Ophthalmology, 119, pp.1575~1581 (2012)
- Ming S, "Efficacy and safety of adalimumab in the treatment of non-infectious uveitis : a meta-analysis and systematic review", Drug Des Devel Ther, 12, pp.2005~2016 (2018)
- Callejas-Rubio JL, "Adalimumab therapy for refractory uveitis : a pilot study", J Ocul Pharmacol Ther, 24, pp.613~614 (2008)
- Diaz-Llopis M, "Adalimumab therapy for refractory uveitis : a pilot study", J Ocul Pharmacol Ther, 24, pp.351~361 (2008)
- Dobner BC, "A three-centre experience with adalimumab for the treatment of non-infectious uveitis", Br J Ophthalmol, 97, pp.134~138 (2013)
- Suhler EB, "Adalimumab therapy for refractory uveitis : results of a multicentre, open-label, prospective trial", Br J Ophthalmol, 97, pp.481~486 (2013)
- Cordero-Coma M, "Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis", Ocul Immunol Inflamm, 21, pp.19~27 (2013)
- Nguyen QD, "Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids(VISUAL II) : a multicentre, double-masked, randomised, placebo-controlled phase 3 trial", Lancet, 388, pp.1183~1192 (2016)
- Petropoulos IK, "Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis : the experience of Jules Gonin Eye Hospital", Klin Monbl Augenheilkd, 225, pp.457~461 (2008)
- Gueudry J, "Anti-tumor necrosis factor-alpha agents in noninfectious uveitis", Dev Ophthalmol, 51, pp.63~78 (2012)
- Guignard S, "Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy : a retrospective study", Ann Rheum Dis, 65, pp.1631~1634 (2006)